Phase 1 IND Frequently Asked Questions

FDA provides answers to sponsors' common questions about Phase 1 Investigational New Drug applications. The FAQ covers early trial objectives, supporting nonclinical evidence, submission processes and options for combining phases, with development programmes reviewed individually.

Why it matters: FDA's FAQ brings together information on study design, nonclinical support and IND processes relevant to sponsors' early trial planning.